ASCO: Agreement Lacking With ESMO on Most Effective Drugs
Negative correlation identified for ASCO benefit score with monthly incremental drug costs
Many Taking NOACs for A-Fib May Not Be Getting Right Dose
Study of newer medications finds 16 percent receive too much or too little
ASCO: Novel Meds Show Promise in Advanced NSCLC
Results presented from two phase III trials
Grass Pollen SLIT Slows Course of Allergic Rhinitis, Asthma
Tx associated with slower AR progression, less frequent asthma onset, slower asthma progression
ASCO: Olaparib Efficacious in BRCA-Related Breast Cancer
May offer a new treatment for women with advanced BRCA-related disease, researchers say
ASCO: Survival Up With Patient-Reported Outcomes During CA Tx
Improved survival with patient-reported outcomes for symptom monitoring in metastatic cancer
ASCO: Gene-Targeted Drug Shows Efficacy for Child, Adult Cancers
Larotrectinib targets tropomyosin receptor kinase fusion proteins
ASCO: Abiraterone Extends Survival in Metastatic Prostate CA
Side effects noted with use of abiraterone similar to those already found in patients taking the drug
Model Predicts Acute GI Bleeding in Anticoagulated Patients
New scoring model includes five factors predictive of GI bleeding in patients taking oral anticoagulants
Reducing SBP Targets Below Current Guidelines Cuts Risk
Reducing SBP to 120 to 124 mm Hg linked to reduced risk of cardiovascular disease, all-cause mortality
